According to a phase 3 study, QL1209, a pertuzumab biosimilar, was found to have comparable efficacy, safety, and immunogenicity to the reference product among patients with HER2-positive breast cancer.
According to a phase 3 study, QL1209, a pertuzumab biosimilar, was found to have comparable efficacy, safety, and immunogenicity to the reference product among patients with HER2-positive breast cancer.
According to a phase 3 study,...